Personalis Inc. Raises Full-Year Revenue Guidance
Personalis sees 35% Q2 revenue growth, lifts full-year outlook to $79-$81M.
- Latest
- Trending
Personalis sees 35% Q2 revenue growth, lifts full-year outlook to $79-$81M.
Explore top biotech stocks poised for growth amid market challenges. Learn about innovations and opportunities in gene therapy.
Aditxt (ADTX) stock is soaring after a major update on a clinical trial for early ovarian cancer detection, driving heavy ...
Veracyte's Q2 revenue surged 27% to $114.4M, fueled by strong demand for genomic tests. Full-year guidance raised to $432M-$438M.
Roche is evaluating options for its $1.9 billion investment in Flatiron Health, potentially including divestment.
McLaren Health Care is experiencing IT and phone system outages, impacting patient services. The health system is working to resolve ...
Castle Biosciences reports 74% Q2 revenue surge to $87M, driven by test usage and price hikes, with net income rebounding ...
Connecticut firefighters sue DuPont, 3M, and Honeywell over cancer-causing PFAS in gear. Learn about the health risks and lawsuit details.
UnityPoint Health-Grinnell introduces Neoprobe Gamma Detection for precise breast cancer surgery, enhancing patient care and personalized treatment.
"AI in Medical Diagnostics set to skyrocket to USD 30.76 billion by 2032, driven by rapid advancements and major industry ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.